A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

NCT03400332 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

281

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Melanoma

Interventions

DRUG: BMS-986253
BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
OTHER: Placebo

Sponsor

Bristol-Myers Squibb